Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Itacitinib · INCB-039110, INCB-39110

Small molecule · Inhibitor of Janus kinase 1 (JAK1) · developed by Incyte

Phase 2 Most advanced trial
INCY Developer
1 Registered trials

What is Itacitinib?

Itacitinib is an orally bioavailable small-molecule inhibitor of Janus kinase 1 (JAK1). It blocks STAT phosphorylation and the production of proinflammatory factors induced by cytokines such as IL-6 and IL-23. It is studied in hematologic and lymphocytic disorders.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
INCB-039110, INCB-39110
Drug type
Small molecule
Targets
Janus kinase 1 (JAK1)
Mechanism
Inhibitor of Janus kinase 1 (JAK1)
Pathways
JAK-STAT signaling, STAT phosphorylation, proinflammatory cytokine production
Therapy area
Hematology
Developer
Incyte Corporation (INCY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
19J3781LPM

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04061421 Phase 1/2 MDS/MPN Recruiting INCY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hematologic and Lymphocytic Disorder

Other drugs acting on JAK1

More from Incyte

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the INCY page.

Follow INCY, the company behind Itacitinib

See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INCY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.